Three Pharmaceutical Drug Group (Wuhu) Co., Ltd.

This product is an adrenal cortex hormone drug. External use can shrink dermal capillaries, inhibit the proliferation or regeneration of epidermal cells, inhibit the regeneration of fibroblasts in connective tissue, stabilize intracellular lysosomal membranes, and prevent tissue damage caused by the release of lysosomal enzymes. It has strong anti-inflammatory and anti-allergic effects.

It can promote blood circulation, reduce inflammation and relieve itching. It can be used for reducing inflammation, relieving itching, relieving pain and reducing edema.

This product (beclomethasone dipropionate) is a potent topical glucocorticoid that can reduce and prevent tissue responses to inflammation, thereby reducing the manifestations of inflammation. Borneol has analgesic and detumescent effects; menthol, when applied topically, has the effects of promoting blood circulation, anti-inflammatory and antipruritic, and can be used for anti-inflammatory, antipruritic, analgesic, and edema reduction; methyl salicylate has a local irritant effect, can promote local blood circulation, and also has an antipruritic effect.

It has a local stimulating effect, can promote local blood circulation, and also has an antipruritic effect

Has analgesic and swelling-reducing effects

This product (beclomethasone dipropionate) is a potent topical glucocorticoid that can reduce and prevent tissue responses to inflammation, thereby reducing the manifestations of inflammation. Borneol has analgesic and detumescent effects; menthol, when applied topically, has the effects of promoting blood circulation, anti-inflammatory and antipruritic, and can be used for anti-inflammatory, antipruritic, analgesic, and edema reduction; methyl salicylate has a local irritant effect, can promote local blood circulation, and also has an antipruritic effect.

It is a potent topical glucocorticoid that reduces and prevents tissue responses to inflammation, thereby alleviating the manifestations of inflammation.

This product is a tetracycline antibiotic. Many rickettsia, mycoplasma, chlamydia, atypical mycobacteria, and spirochetes are sensitive to this product. Enterococci are resistant to it. Due to the widespread use of tetracyclines over the years, common clinical pathogens are seriously resistant to chlortetracycline, and gram-positive bacteria such as staphylococci and most Enterobacteriaceae are resistant. There is cross-resistance between this product and different varieties of tetracyclines. The mechanism of action of this product is that the drug can specifically bind to the A position of the bacterial ribosome 30S subunit, inhibit the growth of the peptide chain and affect the synthesis of bacterial proteins.

This product is a tetracycline antibiotic. Many rickettsia, mycoplasma, chlamydia, atypical mycobacteria, and spirochetes are sensitive to this product. Enterococci are resistant to it. Due to the widespread use of tetracyclines over the years, common clinical pathogens are seriously resistant to chlortetracycline, and gram-positive bacteria such as staphylococci and most Enterobacteriaceae are resistant. There is cross-resistance between this product and different varieties of tetracyclines. The mechanism of action of this product is that the drug can specifically bind to the A position of the bacterial ribosome 30S subunit, inhibit the growth of the peptide chain and affect the synthesis of bacterial proteins.

This product is a tetracycline antibiotic. Many rickettsia, mycoplasma, chlamydia, atypical mycobacteria, and spirochetes are sensitive to this product. Enterococci are resistant to it. Due to the widespread use of tetracyclines over the years, common clinical pathogens are seriously resistant to chlortetracycline, and gram-positive bacteria such as staphylococci and most Enterobacteriaceae are resistant. There is cross-resistance between this product and different varieties of tetracyclines. The mechanism of action of this product is that the drug can specifically bind to the A position of the bacterial ribosome 30S subunit, inhibit the growth of the peptide chain and affect the synthesis of bacterial proteins.

Kanamycin is an aminoglycoside antibiotic that mainly binds to the 30S subunit of bacterial ribosomes and inhibits bacterial protein synthesis. It has a good effect on most Enterobacteriaceae, influenza bacilli, Brucella, meningococci, gonococci, etc. It has a certain effect on methicillin-sensitive strains of Staphylococcus and Mycobacterium tuberculosis, but is ineffective against Pseudomonas aeruginosa. Most other Gram-positive bacteria such as hemolytic streptococci, Streptococcus pneumoniae, enterococci and anaerobic bacteria are resistant. Kanamycin has complete cross-resistance with streptomycin and neomycin, and may have partial cross-resistance with other aminoglycosides.

This product is a broad-spectrum antibacterial agent with bactericidal effect at high concentrations. Many Rickettsia, Mycoplasma, Chlamydia, and Spirochete are sensitive to this product. Enterococci are resistant to it. This product has certain antibacterial activity against Neisseria gonorrhoeae, but penicillin-resistant gonococci are also resistant to tetracycline. Due to the widespread use of tetracyclines over the years, common clinical pathogens are seriously resistant to tetracycline, including Gram-positive bacteria such as Staphylococcus and most Enterobacteriaceae. There is cross-resistance between this product and different varieties of tetracyclines. The mechanism of action of this product is that the drug can specifically bind to the A position of the 30S subunit of the bacterial ribosome, inhibit the growth of the peptide chain and affect the synthesis of bacterial proteins.